Regulation of the HIF-1α stability by histone deacetylases
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Histone deacetylase inhibitors (HDACIs) are currently in clinical trials partly due to their potent anti-angiogenic effects. However, the detailed mechanism of their action is unclear. Here, we observed that several HDACIs (TSA, SB, Apicidin, and VPA) dramatically decreased HIF-1alpha protein level and transcriptional activity of HIF-1 in human and mouse tumor cell lines. Furthermore, class I HDACs, HDAC1 and 3 enhanced HIF-1alpha stability and HIF-1 transactivation function in hypoxic conditions. In addition, immunoprecipitation and in vitro binding assays revealed that HDAC1 and 3 directly bind to the oxygen-dependent degradation domain of HIF-1alpha. Collectively, these results suggest that HDAC1 and 3 are considered as a positive regulator of HIF-1alpha stability via direct interaction and may play an important role in HIF-1-induced tumor angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510
Histone acetylation in chromatin structure and transcription
Grunstein, M. (1997) · Nature · doi:10.1038/38664 · Cited by 2,884
Regulation of angiogenesis by hypoxia: role of the HIF system
Pugh, C. W., & Ratcliffe, P. J. (2003) · Nature Medicine · doi:10.1038/nm0603-677 · Cited by 2,520
HDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403
Three proteins define a class of human histone deacetylases related to yeast Hda1p
Grozinger, C. M., Hassig, C. A., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4868 · Cited by 770
Gao, L., Cueto, M. A., Asselbergs, F., & Atadja, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111871200 · Cited by 744
In vivo destabilization of dynamic microtubules by HDAC6‐mediated deacetylation
Matsuyama, A., Shimazu, T., Sumida, Y., Saito, A., Yoshimatsu, Y., Seigneurin‐Berny, D., Osada, H., Komatsu, Y., Nishino, N., Khochbin, S., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf682 · Cited by 720
Histone deacetylase inhibitors as new cancer drugs
Marks, P. A., Richon, V. M., Breslow, R., & Rifkind, R. A. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00010 · Cited by 531
Hu, E., Chen, Z., Fredrickson, T., Zhu, Y., Kirkpatrick, R., Zhang, G.-F., Johanson, K., Sung, C.-M., Liu, R., & Winkler, J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m908988199 · Cited by 309
Cited by
Histone Deacetylase Inhibitors: Overview and Perspectives
Dokmanovic, M., Clarke, C., & Marks, P. A. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0324 · Cited by 1,164
Histone deacetylases as regulators of inflammation and immunity
Shakespear, M. R., Halili, M. A., Irvine, K. M., Fairlie, D. P., & Sweet, M. J. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.04.001 · Cited by 546
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Khan, O., & La Thangue, N. B. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.100 · Cited by 450
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
The epigenetics of aging and neurodegeneration
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D., Coleman, P., Lemere, C. A., Hof, P. R., van den Hove, D. L. A., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.002 · Cited by 381
Korbecki, J., Simińska, D., Gąssowska-Dobrowolska, M., Listos, J., Gutowska, I., Chlubek, D., & Baranowska-Bosiacka, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910701 · Cited by 380
The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy
Albadari, N., Deng, S., & Li, W. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1613370 · Cited by 351
HDAC inhibitor‐based therapies: Can we interpret the code?
New, M., Olzscha, H., & La Thangue, N. B. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.003 · Cited by 310
Rapid changes in histone deacetylases and inflammatory gene expression in expert meditators
Kaliman, P., Álvarez-López, M. J., Cosín-Tomás, M., Rosenkranz, M. A., Lutz, A., & Davidson, R. J. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.11.004 · Cited by 300
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
Grant, C., Rahman, F., Piekarz, R., Peer, C., Frye, R., Robey, R. W., Gardner, E. R., Figg, W. D., & Bates, S. E. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.88 · Cited by 291
Histone deacetylase inhibitors: Anticancer compounds
Smith, K. T., & Workman, J. L. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.09.008 · Cited by 90
Fazzone, W., Wilson, P. M., LaBonte, M. J., Lenz, H., & Ladner, R. D. (2009) · International Journal of Cancer · doi:10.1002/ijc.24403 · Cited by 80
Ayrapetov, M. K., Xu, C., Sun, Y., Zhu, K., Parmar, K., D'Andrea, A. D., & Price, B. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026064 · Cited by 41
Regulation of hypoxia-inducible factor functions in the nucleus by sphingosine-1-phosphate
Hait, N. C., Maiti, A., Xu, P., Qi, Q., Kawaguchi, T., Okano, M., Takabe, K., Yan, L., & Luo, C. (2020) · The FASEB Journal · doi:10.1096/fj.201901734rr · Cited by 41
Bohonowych, J. E., Peng, S., Gopal, U., Hance, M. W., Wing, S. B., Argraves, K. M., Lundgren, K., & Isaacs, J. S. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-520 · Cited by 32
Fu, C., Tyagi, R., Chin, A. C., Rojas, T., Li, R.-J., Guha, P., Bernstein, I. A., Rao, F., Xu, R., Cha, J. Y., et al. (2018) · Circulation Research · doi:10.1161/circresaha.117.311983 · Cited by 28
HIF-dependent and reversible nucleosome disassembly in hypoxia-inducible gene promoters
Suzuki, N., Vojnovic, N., Lee, K.-L., Yang, H., Gradin, K., & Poellinger, L. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.03.020 · Cited by 21
Metadata
- Authors
- Kim, S.-H., Jeong, J.-W., Park, J., Lee, J.-W., Seo, J., Jung, B.-K., Bae, M.-K., & Kim, K.-W.
- Venue
- Oncology Reports
- Publisher
- Spandidos Publications
- Published
- 2007-03-01
- Volume
- 17
- Issue
- 3
- Pages
- 647-51
- ISSN
- 1021-335X (ISSN-L)
- 1791-2431
- OpenAlex
- W2058582218
- Cited by
- 144
- References
- 13
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.